| 2025-02-12 | +0.61 % |
|
| 2025-02-11 | +0.78 % |
|
| 2025-02-07 | -1.23 % |
|
| 2025-02-06 | +0.64 % |
|
| 2025-02-05 | +0.95 % |
- AbbVie (ABBV) stock increased by 0.95% following a price target raise from Guggenheim from $212.00 to $214.00, along with several other analysts upgrading their ratings and target prices, suggesting strong investor confidence in the stock's potential.
- AbbVie (ABBV) stock rose by 0.95% after analysts at Raymond James reaffirmed their "outperform" rating and increased the target price from $218.00 to $220.00, indicating a potential upside, while a consensus of analysts maintains a "Moderate Buy" rating on the stock.
- AbbVie (ABBV) stock rose by 0.95% following Jim Cramer's endorsement on "Mad Money," where he highlighted the company's potential and success with its immunosuppressive drugs, suggesting it's undervalued despite recent declines.
The stock's increase can be attributed to positive analyst sentiment, particularly from Cramer, and AbbVie's strong performance in the biopharma sector, especially with its drugs Skyrizi and Rinvoq, providing reassurance to investors amid market uncertainties.
- AbbVie (ABBV) stock rose 0.95% following a target price increase from Truist Financial from $211.00 to $217.00, reflecting a positive outlook and a "buy" rating by the brokerage.
- AbbVie (ABBV) stock increased by 0.95% after UBS Group raised its price target from $181.00 to $190.00, indicating continued positive analyst sentiment toward the company's future performance despite a recent earnings miss.
|
| 2025-02-04 | -0.1 % |
|
| 2025-02-03 | +3.39 % |
|
| 2025-01-31 | +4.7 % |
|
| 2025-01-28 | -1.18 % |
|
| 2025-01-27 | +3.88 % |
|
| 2025-01-24 | -0.22 % |
|
| 2025-01-23 | +0.87 % |
|
| 2025-01-22 | -1.98 % |
|
| 2025-01-17 | -1.23 % |
|
| 2025-01-16 | +1.37 % |
|
| 2025-01-15 | -2.39 % |
|
| 2025-01-13 | +0.9 % |
|
| 2025-01-10 | -1.87 % |
|
| 2025-01-06 | -0.62 % |
|
| 2025-01-03 | +0.99 % |
- AbbVie Inc. (NYSE:ABBV) saw its stock rise by 0.99% last night due to increased institutional investor holdings and positive analyst ratings, despite some mixed views on its stock performance.
The stock rose primarily because institutional investors, like Old Port Advisors, have been increasing their holdings, signaling confidence in AbbVie's potential, alongside favorable analyst ratings and an increase in their quarterly dividend.
- AbbVie Inc. (ABBV) stock rose by 0.99% following a significant increase in institutional investments, particularly from Versant Capital Management Inc, which raised its holdings in the company by 33.9% during the fourth quarter, along with positive earnings results and a favorable dividend announcement.
- AbbVie (ABBV) stock rose 0.99% due to increased institutional investment, positive quarterly earnings results that exceeded estimates, and a recently announced dividend hike, contributing to a favorable outlook from analysts.
|
| 2025-01-02 | +0.98 % |
|
| 2024-12-30 | -1.02 % |
|
| 2024-12-26 | -0.44 % |
|
| 2024-12-20 | +2.37 % |
|
| 2024-12-19 | -0.87 % |
|
| 2024-12-18 | -1.35 % |
|
| 2024-12-17 | +2.18 % |
|
| 2024-12-16 | -1 % |
|
| 2024-12-12 | -0.68 % |
|
| 2024-12-10 | -0.51 % |
|
| 2024-12-06 | +0.01 % |
|
| 2024-12-02 | -0.63 % |
|
| 2024-11-29 | -0.08 % |
|
| 2024-11-27 | +1.07 % |
|
| 2024-11-25 | +0.06 % |
|
| 2024-11-21 | +2.37 % |
|
| 2024-11-20 | +0.71 % |
|
| 2024-11-18 | +0.78 % |
|
| 2024-11-14 | -0.42 % |
|
| 2024-11-12 | -1.91 % |
|
| 2024-11-11 | -12.57 % |
- AbbVie Inc (NYSE:ABBV) stock fell by 12.57% after the company released disappointing results from its Phase 2 EMPOWER trials of emraclidine, an oral treatment for schizophrenia, which may have raised concerns about the drug's efficacy.
- AbbVie Inc.'s (ABBV) stock fell by 12.57% after two Phase 2 trials for emraclidine, an oral treatment for schizophrenia, failed to meet their primary endpoints, disappointing Wall Street expectations for positive results.
- AbbVie Inc (NYSE:ABBV) stock fell by 12.57% after the company reported that two Phase 2 trials for emraclidine, its oral treatment for schizophrenia, failed to meet their primary endpoints.
- AbbVie (ABBV) stock fell by 12.57% following the announcement that two Phase 2 trials of its schizophrenia treatment emraclidine failed to meet their primary endpoints.
- AbbVie Inc. shares plunged over 12% after two mid-stage trials for its schizophrenia drug, emraclidine, failed to show significant improvement compared to a placebo, raising concerns about its recent $8.7 billion acquisition of Cerevel Therapeutics and impacting investor sentiment.
|
| 2024-11-06 | -0.24 % |
|
| 2024-11-04 | -1.51 % |
|
| 2024-11-01 | -0.16 % |
|
| 2024-10-30 | +6.36 % |
|
| 2024-10-29 | -0.12 % |
|
| 2024-10-28 | +0.97 % |
|
| 2024-10-25 | -0.95 % |
|
| 2024-10-24 | +0.94 % |
|
| 2024-10-23 | -0.47 % |
|
| 2024-10-22 | +1.19 % |
- AbbVie (ABBV) stock rose by 1.19% following a significant 79% increase in stakes by Foundations Investment Advisors LLC, indicating strong investor confidence and potential positive sentiment towards the company's performance.
- AbbVie (ABBV) stock increased by 1.19% following the FDA’s approval of SELARSDI, a new biosimilar treatment for conditions treated by its reference product, Stelara, developed by Johnson & Johnson, which is expected to compete in the market and potentially affect AbbVie's market share significantly.
- AbbVie (ABBV) stock rose by 1.19% following the FDA's approval of the biosimilar SELARSDI (ustekinumab-aekn) by Alvotech and Teva Pharmaceuticals, which aligns its label with the original product Stelara® and enhances market competition in the biosimilars segment, potentially influencing AbbVie's market positioning.
- AbbVie (ABBV) stock rose by 1.19% as it continues to demonstrate stronger revenue and earnings compared to Nuvectis Pharma, alongside robust institutional ownership, which suggests positive long-term growth expectations from investors.
- AbbVie (ABBV) stock was up 1.19% last night, reflecting positive market sentiment, potentially due to strong quarterly earnings, favorable drug developments, or overall investor confidence in the company's future growth prospects.
|
| 2024-10-21 | -1.23 % |
|
| 2024-10-18 | +0.15 % |
|
| 2024-10-17 | -0.99 % |
|
| 2024-10-16 | -0.73 % |
|
| 2024-10-15 | -1.94 % |
|
| 2024-10-14 | +0.75 % |
|
| 2024-10-11 | -0.08 % |
|
| 2024-10-10 | -0.21 % |
|
| 2024-10-09 | +0.9 % |
- AbbVie (ABBV) stock rose by 0.9% last night, driven by increased institutional buying, positive analyst ratings with raised price targets, and strong earnings results that surpassed expectations.
- AbbVie Inc. (ABBV) shares experienced a slight increase of 0.9% as trading volume significantly declined, suggesting limited investor activity; the stock's upward movement may be attributed to positive market sentiment or specific company developments.
- AbbVie Inc. (ABBV) stock rose 0.9% following new investments from institutional investors and optimistic analyst ratings, reflecting confidence in the company's continual revenue growth and solid quarterly earnings performance.
The stock's increase can be attributed to significant institutional interest, with multiple large investors acquiring shares, as well as positive commentary and target price upgrades from several brokerages, indicative of a strong market outlook for AbbVie.
- AbbVie (ABBV) stock rose by 0.9% due to strong recent earnings performance that exceeded analysts' expectations, alongside positive investor sentiment reflected in increased institutional holdings and several analysts raising their price targets on the stock.
- AbbVie (ABBV) stock rose 0.9% following an increase in its target price by UBS Group from $185.00 to $195.00, indicating positive sentiment from analysts despite maintaining a "neutral" rating.
|
| 2024-10-08 | -0.31 % |
|
| 2024-10-07 | -0.35 % |
|
| 2024-10-04 | -0.59 % |
|
| 2024-10-03 | -0.7 % |
|
| 2024-10-02 | -0.07 % |
|
| 2024-10-01 | -0.26 % |
|
| 2024-09-30 | +1.38 % |
|
| 2024-09-27 | +1.51 % |
|
| 2024-09-26 | +0.33 % |
- AbbVie (ABBV) stock rose by 0.33% due to its strong dividend profile, demonstrating financial resilience with revenue growth following the loss of patent exclusivity for its leading product, Humira, supported by the continued success of its successor drugs, Skyrizi and Rinvoq, and a robust pipeline of new products.
- AbbVie Inc. (ABBV) stock experienced a slight increase of 0.33%, trading at $191.40 amidst lower-than-average trading volume, potentially indicating investor confidence or positive sentiment surrounding the company.
- AbbVie (ABBV) stock experienced a 0.33% increase last night, driven by its superior revenue growth and profitability compared to Bristol Myers Squibb (BMY), despite the latter being viewed as better valued based on revenue multiples.
- AbbVie (ABBV) stock rose by 0.33% as investor enthusiasm for biopharmaceuticals continues, possibly influenced by the success of companies like Summit Therapeutics and the advancements in cancer treatments, which highlight the industry's potential for rapid growth and high returns.
- AbbVie (ABBV) stock rose by 0.33% despite Fred Alger Management LLC reducing its holdings by 24.0% in the 2nd quarter, indicating potential investor interest and market resilience.
|
| 2024-09-25 | -1.16 % |
|
| 2024-09-24 | -0.17 % |
|
| 2024-09-23 | +0.19 % |
|
| 2024-09-20 | -0.08 % |
|
| 2024-09-17 | -1.16 % |
|
| 2024-09-16 | +0.78 % |
|
| 2024-09-13 | +0.1 % |
|
| 2024-09-10 | +1.49 % |
|
| 2024-09-09 | +1.56 % |
|
| 2024-09-06 | +0.28 % |
|
| 2024-09-05 | -2.11 % |
|
| 2024-09-04 | -0.34 % |
|
| 2024-09-03 | +0.7 % |
|
| 2024-08-30 | +0.58 % |
|
